Virtual Care | Glytec

May 16, 2019

Glytec Awarded Patent Allowance for Virtual Insulin Titration in Concert with CGM, Smart Pens and Other Diabetes Technologies

The company’s growing intellectual property portfolio attests to its leadership position in diabetes medication optimization in an era of data-driven care.

Glytec, the pioneer of digital therapeutics, has been awarded another patent allowance by the United States Patent and Trademark Office (USPTO). The latest allowance references interactions between the company’s software-as-a-medical-device platform for insulin titration and multiple connected diabetes technologies, including continuous glucose monitoring (CGM) systems, smart insulin pens and insulin pumps.

May 14, 2019

Glytec and Onduo to Deliver Webinar on Virtual Diabetes Care in Partnership with HIMSS

The May 30, 2019 webinar will explore the keys to augmenting traditional brick-and-mortar care with virtual care for people with diabetes.

Managing the care of people with diabetes is costly and time intensive, especially for our nation’s primary care providers who shoulder 80% of that responsibility. Virtual care programs have the potential to fill critical gaps and meet increasing demands, but can they produce real results?

June 6, 2018

Glytec Adds Smart Meter to Growing Network of Connected Solution Partners

The iGlucose® Cell-Enabled Diabetes Care Solution from Smart Meter is now compatible with Glytec’s virtual insulin titration service.

For millions of patients with diabetes who’ve been unable to achieve their treatment goals, few programs have the potential to reduce A1C faster or more effectively than Glytec’s virtual insulin titration service. The innovative service harnesses the integration of Glytec’s Glucommander™ Outpatient software with multiple connected diabetes technologies and health information systems, including those for blood glucose measurement, insulin delivery, medical record keeping and patient communication, among others. The latest company to join Glytec’s network of connected solution partners is Smart Meter, LLC, maker of the iGlucose® Cell-Enabled Diabetes Care Solution, bringing timely, complete and accurate data to insulin titration.

February 15, 2018

Study Shows Computer-Guided Insulin Dosing Plus More Frequent Blood Glucose Testing Leads to Better Outcomes for Patients with Diabetes

New study in which insulin dosing was guided by Glytec’s Glucommander™ Outpatient observed markedly greater reductions in A1c among patients who tested blood glucose twice a day or more.

A retrospective study being presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) observed that use of Glytec’s Glucommander™ Outpatient for insulin therapy management combined with blood glucose self-testing at least twice a day resulted in better patient outcomes, including a 3.0% absolute reduction in A1c and virtually no hypoglycemia (0.003%) less than 54 mg/dL.

January 23, 2018

Glytec’s Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology

Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.

Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.

September 19, 2017

New Research Shows People on Insulin For Diabetes Maintain A1C Reductions Through Digital Therapy Management

A study presented at EASD 2017 shows long-term A1C reductions through personalized insulin dose adjustments every eight weeks using Glytec’s therapy management software.

More than 50 percent of all people using insulin to manage diabetes are not at their target A1C, which is why this high-risk population is a primary focus of value-based care strategies among providers and payers alike. A retrospective study presented at the Annual Meeting of the European Association for the Study of Diabetes shows that patients whose insulin therapy is guided by Glytec’s FDA-cleared Glucommander™ software not only achieve glucose control rapidly, but with ongoing personalized dose adjustments, successfully maintain A1C reductions long term.

June 8, 2017

AgaMatrix and Glytec Announce Partnership to Deliver a Cloud-Based Diabetes Management Platform to Improve Clinical Insights and Patient Blood Glucose Control

AgaMatrix, Inc. and Glytec announced today they are partnering to optimize clinical access to accurate glucose data and insulin titration support through a cloud-based diabetes management platform.

AgaMatrix is integrating their FDA-cleared Jazz Wireless 2 Bluetooth® Blood Glucose Monitoring System with Glytec’s eGlycemic Management System® (eGMS®), featuring FDA-cleared Glucommander™ for evidence-based insulin dosing decision support. By automatically transferring patient blood glucose data from the AgaMatrix Diabetes Manager App to eGMS®, health care professionals are able to deliver personalized diabetes therapy management in a virtual setting. The two companies are actively engaged in a pilot of this integrated solution.